enoxaparin

ApprovedCompleted
1 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Venous Thrombosis

Conditions

Venous Thrombosis

Trial Timeline

Dec 1, 2004 → Jan 1, 2009

About enoxaparin

enoxaparin is a approved stage product being developed by Sanofi for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00265993. Target conditions include Venous Thrombosis.

What happened to similar drugs?

5 of 20 similar drugs in Venous Thrombosis were approved

Approved (5) Terminated (3) Active (13)
ApixabanBristol Myers SquibbApproved
enoxaparin sodiumSanofiApproved
Long DOAC + Short DOACBayerApproved
🔄Edoxaban + Standard of CareDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT04492254Phase 3Terminated
NCT00908960Phase 2Completed
NCT00518245ApprovedTerminated
NCT00622115Phase 1Completed
NCT00723216Phase 3Completed
NCT00444652ApprovedUNKNOWN
NCT00769873Phase 2Terminated
NCT00413374Pre-clinicalCompleted
NCT00265993ApprovedCompleted
NCT00043784Phase 3Completed
NCT00289042ApprovedCompleted

Competing Products

20 competing products in Venous Thrombosis

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
26
dalteparin injectionEisaiPhase 3
32
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
29